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doi:10.1016/j.ejvs.2011.01.018Abstract Objectives: This cohort study assesses the effectiveness and safety of endovenous
laser ablation (EVLA) in the management of recurrent varicose veins (RVVS).
Method: 104 limbs (95 patients) undergoing EVLA for RVVS were grouped according to pattern
of reflux. For patients with recurrent SFJ/great saphenous vein (GSV) (Group GR) and SPJ/
small saphenous vein (SSV) (Group SR) varicosities ablation rates and QoL (Aberdeen Varicose
Vein Severity Scores (AVVSS)) were compared with those for age/sex matched patients under-
going EVLA for primary GSV/SSV dependent varicose veins (Groups GP and SP).
Results: In patients with RVVS the axial vein was ablated in 102/104 (98%) limbs whilst 2 GSVs
(group GR) partially recanalised by 3 months (GSV ablated in 49/51 (96%) limbs versus 50/51
(98%) limbs in GP [pZ 0.2]). Improvements in AVVSS at 3 months (median GR: 14.2 (inter-quar-
tile range (IQR) 10.2e18.9) to 3.2(1.2e6.4), p < 0.001; GP: median 15.9(IQR 11.4e22.7) to 3.8
(1.1e5.6), p < 0.001, ManneWhitney u-test) were similar (78% versus 76%, pZ 0.23). The SSV
was ablated in 24/24 limbs in groups SR and SP and the % improvement in AVVSS was 83%
(median 14.4 (IQR 8.2e19.4) to 2.4 (1.9e4.6), p < 0.001, ManneWhitney u-test) and 84%
(median 13.8 (IQR 6.3e17.5) to 2.2 (1.2e5.1), p < 0.001) respectively (p Z 0.33). These
improvements persisted at 1 year follow-up. A further 29 limbs with isolated anterior accessory
great saphenous vein (AAGSV) or segmental GSV/SSV reflux were successfully ablated. Compli-
cation rates for primary and RVVS were similar.
Conclusions: EVLA is a safe and effective option for the treatment of RVVS and could be
a preferred option for suitable patients.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Recurrent varicose veins (RVVS) following surgery are
relatively common and treatment of these accounts for3 3922823; fax: þ44 113 3922624
rksandhumber.nhs.uk (M.J. Goug
ty for Vascular Surgery. Publishesome 20% of the venous workload.1 Reasons for recurrence
following previous sapheno-femoral or sapheno-popliteal
ligation include technically inadequate primary surgery,
failure to accurately identify the source of reflux prior to.
h).
d by Elsevier Ltd. All rights reserved.
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of reflux or neovascularisation at deep/truncal vein junc-
tions. The latter is thought to be the commonest cause of
recurrence.2 Whilst re-do surgery is generally considered
the standard therapy for these patients it can be techni-
cally challenging, time consuming and associated with
a greater risk of complications.3e5 This study assesses the
role, efficacy and safety of endovenous laser ablation
(EVLA) in the treatment of RVVS associated with great
saphenous (GSV), anterior accessory great saphenous
(AAGSV) or small saphenous vein (SSV) incompetence.
Methods
Patients
Patients attending the venous clinic at the General Infir-
mary at Leeds with RVVS were assessed with a duplex
ultrasound scan (DUS), (TITAN, Sonosite Inc, Bothell, USA)
to assess their suitability for EVLA. Criteria for this were the
presence of a residual GSV, AAGSV or SSV demonstrating
significant reflux (>1s) which was identified as the source of
the recurrent varicosities. In general patients were only
selected for EVLA provided that at least 10 cm of truncal
vein (with a diameter of >3 mm) proximal to the varicosi-
ties could be ablated. This length is a local guideline to
ensure that reflux is obliterated. The presence of neo-
vascularisation did not precluded EVLA although any
recurrent varicosities that connected directly to these
vessels, to an incompetent perforating vein or to pelvic
veins without an intervening axial vein were considered
unsuitable for EVLA. Fig. 1 illustrates the possible patterns
of recurrence and their suitability for EVLA.
For patients meeting the inclusion criteria EVLA was
offered in preference to conventional surgery and this
study includes 95 consecutive patients (104 limbs; male:
35 female: 60, median age 56 [IQR 42e74]) who under-
went EVLA for RVVS between March 2005 and March 2007
and completed a minimum of 3 months follow-up. Ethical
approval was obtained from the local ethics committee
and all participants were consented for the procedure and
for data collection. Of these, 47 and 23 patients had iso-
lated GSV and SSV reflux respectively (Groups GR and SR)
to account for their recurrence. Their outcomes have
been compared to age and sex matched patients who had
EVLA for primary varicose veins (Groups GP and SP) during
the same period. Demographic data and the CEAP classi-
fication for these patients are shown in Table 1. During the
same period 32 patients who were not suitable for EVLA
were treated surgically. Patients whose “recurrent” vari-
cosities were the result of new sapheno-popliteal or
sapheno-femoral reflux following previous ligation of the
other deep/truncal junction were not included in the
study.
EVLA technique
Target axial vein ablation (residual GSV, AAGSV or SSV) was
achieved by endovenous application of laser energy
(810 nm diode laser, 12 W power, 60 J/cm energy) under
tumescent local anaesthesia as an out-patient procedure.Full details of the technique for GSV6 and SSV7 ablation
have been described previously.
When treating the GSV the guide-wire often failed to
enter into the common femoral vein and thus the sheath
was advanced as far as possible without piercing the vein
wall. The tip of the sheath was visualised (DUS) to confirm
its position within the truncal vein. In patients in whom this
connected to the deep vein via neovascularisation, these
were filled with 1e2 ml 3% sodium tetradecyl sulphate foam
(STD) prepared according to Tessari’s method8(Fibro-vein,
STD Pharmaceutical Products Ltd, Hereford, England) via
the endovenous catheter (ELVeS Plus Katheter; Biolitec
Group, Bonn, Germany) before introducing the laser fibre.
Foam was administered with the patient in the Trendelen-
burg position and its progress monitored with DUS to mini-
mise egress of sclerosant into the common femoral vein. No
sclerotherapy was performed for the superficial varicosities
at the time of EVLA. Following treatment a compression
bandage was applied for 1 week followed by a grade 2
compression stocking for a further week. Residual varicos-
ities were treated by delayed foam sclerotherapy at 6
weeks when requested by the patient.
Data collection
Pre-treatment venous clinical severity score (VCSS), CEAP
classification and Aberdeen Varicose Vein Severity Scores
(AVVSS), the length of vein treated, the laser energy delivered
(J/cm) and administration of foam sclerotherapy to the neo-
vessels were recorded for all patients. Data for the control
groups was obtained from a prospectively maintained data-
base of all patients undergoing EVLA at our institution.
Patients were followed up at 6, 12 and 52 weeks when
DUS was performed to identify persisting deep to superficial
vein reflux, whether the treated truncal vein had been
successfully ablated and the presence or absence of a deep
vein thrombosis. At each visit the requirement for scle-
rotherapy were recorded. Post-treatment VCSS and AVVSS
were determined at 12 weeks and a prospective log of
complications was maintained throughout the study.
Statistical analysis
The VCSS and AVVSS before and after laser ablation were
compared within a group using a Wilcoxon test and the
improvements in AVVSS between groups were compared by
a ManneWhitney u-test. A p value of <0.05 was considered
significant. Data are presented as median (inter-quartile
range) unless stated otherwise. All analysis were performed
by statistical package SPSS for Windows (SPSS (14), Chi-
cago, Illinois, USA).
Results
Patients’ demographic details and the CEAP grades for each
group are detailed in table 1 and the DUS-identified cause
of recurrence is shown in Table 2.
Overall, complete truncal vein ablation was achieved in
102/104 (98%) limbs. Following GSV ablation the vein was
successfully treated in 49/51 (96%) limbs in Group GR whilst
2/51 (4%) had partially recanalised by 3 months. Treatment
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Figure 1 Patterns of RVVS and their suitability for laser (upper row veins are suitable for EVLA while the lower row veins are not).
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group was compared to those undergoing EVLA for primary
GSV reflux (Group GP) there was no difference in ablation
rates (50/51 (98%), pZ 0.2 versus GR) or in the improvement
in AVVSS (p Z 0.23) at 12 weeks. Both groups showed
a significant improvement in these scores from baseline
(p < 0.001). These results are summarised in Table 4 as are
those for the VCSS assessments. Delayed foam sclerotherapyTable 1 Patterns of recurrent varicosities treated by
EVLA.
Types of recurrence Limbs (patients) %
Recurrent GSV  groin
neovascularisation
51 (47) 49%
Recurrent SSV reflux  popliteal
neovascularisation
24 (23) 23%
AAGSV  groin neovascularisation 11 (9) 10%
Incompetent perforator with
distal GSV reflux
6 (6) 6%
Residual GSV supported by
reflux from pelvic vein
4 (4) 4%
> 1 source of reflux
(combinations of above)
8 (6) 8%
Total 104 (95) 100%was required in 19/51 (37%) limbs in group GR and 20/51
(39%) of GP legs (pZ 0.5). Three and 5 patients developed
symptomatic post-sclerotherapy phlebitis in groups GR and
GP respectively (pZ 0.36). Patient satisfaction was similar
in both groups (GR 86%, GP 82%; pZ 0.32).
Although groin neovascularisation was treated with foam
sclerotherapy in 24/51 limbs in group GR 19/24 had
evidence of persisting neo-vessels on DUS at 12 weeks. In
this sub-group the GSV was completely ablated in 23/24
limbs with a similar improvement in AVVSS to group GR
overall (13.6 (8.5e17.7) to 2.8 (0.5e4.3), p < 0.001). The %
improvement in AVVSS (79%) was also similar to that of the
whole group (78%, p Z 0.24).
Treatment of SSV reflux was successful in all 24 limbs in
groups SR and SP. This was associated with a similar
(pZ 0.33) improvement in AVVSS (p < 0.001) in both groups
(Table 4). Delayed foam sclerotherapy was required in 8/24
(SR; 33%) and 6/24 (SP; 25%) limbs respectively (pZ 0.38).
Two SR and 3 SP patients experienced post-sclerotherapy
phlebitis (p Z 0.5) and patients satisfaction scores were
similar: SR 88%, SP 90% (p Z 0.42).
In patients undergoing EVLA for AAGSV incompetence
11/11 were treated successfully with a significant
improvement in the AVVSS, p < 0.001 (Table 4). Delayed
foam sclerotherapy was required in 6/11 (54%) limbs and
patient satisfaction was 78%. None experienced phlebitis
after EVLA although 2 patients suffered post-sclerotherapy
thrombophlebitis.
Table 2 Patients’ demography and disease severity scores for the study groups (GR, SR) and their age and sex matched control
groups (GP, SP).
Group GR Group GP Group SR Group SP
Number of patients (limbs) 47 (51) 47 (51) 23 (24) 23 (24)
Age median (IQR) 52 (42e68) 52 (42e68) 49 (33e65) 49 (33e65)
Male:Female 20:27 20:27 9:14 9:14
C2 of CEAP 27 (53%) 30 (59%) 10 (42%) 11 (46%)
C3 of CEAP 9 (17.6%) 7 (14%) 7 (29%) 8 (33%)
C4 of CEAP 10 (19.6%) 11 (21%) 5 (21%) 4 (17%)
C5/6 of CEAP 5 (9.8%) 3 (6%) 2 (8%) 1 (4%)
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successful GSV ablation following which all perforators
regained competency (unidirectional flow during distal calf
compression and release). Two patients required delayed
foam sclerotherapy. Again the AVVSS improved significantly
(p Z 0.004, Table 4) and 76% patients were satisfied with
the outcome. Similarly all 4 GSVs with reflux supported by
pelvic vein reflux were successfully ablated although the
untreated vein communicating with the pelvic veins
remained patent with minimal reflux (<1s).
No patient showed evidence of deep vein thrombosis
during the follow-up. Although 1 patient in group SP had
transient numbness in the distribution of the sural nerve
this had resolved by 6 months. No neurological symptoms
were recorded in any other patient. The overall inci-
dence of symptomatic post-sclerotherapy phlebitis was
7/104 (7%) following EVLA for RVVS. This was treated
with a 1e2 week course of diclofenac sodium 50 mg three
times per day.
1 year follow-up was completed in 74/85 patients (79/92
limbs) in groups GR and SR and patients with recurrence
secondary to perforator or AAGSV reflux. Similarly in groups
GP and SP 65/70 patients (65/75 limbs) were reviewed at
this time. DUS confirmed that all successfully treated veins
remained ablated with no instances of recanalisation.
Further, the improvements in both AVVSS and VCSS per-
sisted and patient satisfaction (linear analogue scale) was
high: 91% of groups GR and SR were pleased with their
outcome compared to 88% with primary varicose veins. The
results are summarised in Table 5.Table 3 Treatment details and size of the veins for the study (GR
the median and inter-quartile range (IQR)).
Group GR Group GP Pa (GR v G
Number
of limbs
51 51 e
Total laser
energy (J)
2116
(IQR 1392e2591)
1998
(IQR 1317e2580)
0.23
Energy density
(J/cm)
61 (IQR 52e66) 60 (IQR 52e64) 0.32
Diameter of the
vein (mm)
7.6
(IQR 5.3e8.0)
7.7
(IQR 5.7e8.2)
0.41
Length of vein
(cm)
36 (IQR 28e41) 34 (IQR 27e40) 0.21
a ManneWhitney u-test.Discussion
Recurrence following varicose vein surgery is common after
both sapheno-femoral and sapheno-popliteal ligation. Most
recurrent varicose (65%) veins are due to reflux at the SFJ9
and this may result in reflux into a residual GSV or AAGSV.
Alternative causes of recurrent GSV reflux include an
incompetent perforating vein in the thigh or proximal calf
or a residual GSV may establish a communication with veins
that drain into pelvis, often via the perineum. For these
routine re-exploration of the groin would be unnecessary.
Recurrence following sapheno-popliteal surgery is rela-
tively more common and occurs in up to 60%9 of patients
after sapheno-popliteal ligation. The causes include failure
to ligate the SPJ and the non-stripped SSV regaining
a communication with the popliteal vein via neo-
vascularisation. Rashid et al. found that the former was the
case in some 22% of patients despite pre-operative DUS
marking of the SPJ.10 Re-exploration of the SPJ can be
difficult and has rarely been associated with major nerve
injury. Thus minimally invasive treatment is an attractive
option.
Although GSV stripping is associated with lower recur-
rence rates11 in the absence of pre-operative ultrasound
marking and quality control, which is rarely performed,
Jiang et al.9 found that a residual GSV was present in 43% of
the patients who had previously undergone high tie with
GSV stripping. Similarly, many patients with recurrent GSV
varicosities in this series appeared as if the GSV had not
been stripped despite the belief that it had. Whilst some of, SR) and control (GP, SP) groups. (All data are represented by
P) Group SR Group SP P
(SR v SP)
AAGSV
24 24 e 11
1286
(IQR 910e1520)
1254
(IQR 899e1498)
0.28 1360
(990e1620)
64 (IQR 55e69) 66 (IQR 56e71) 0.36 62 (57e66)
7.4
(IQR 4.2e8.1)
7.2
(IQR 4.1e8.0)
0.29 6.3
(4.6e7.4)
20 (IQR 16e22) 19 (IQR 16e21) 0.43 22
(IQR 16e28)
Table 4 Comparison of AVVSS and VCSS scores 6 weeks post-EVLA. (All data are represented by the median and inter-quartile
range).
Groups Pre treatment
AVVSS
Post treatment
AVVSS
Pa (pre-post EVLA) % Improvement AVVSS Pre EVLA
VCSS
Post EVLA
VCSS
GR 14.2 (10.2e18.9) 3.2 (1.2e6.4) <0.001 78 GR v GP [p Z 0.23] 4 (3e5) 1 (0e2)
GP 15.9(11.4e22.7) 3.8 (1.1e5.6) <0.001 76 4 (3e5) 1 (0e2)
SR 14.4 (8.2e19.4) 2.4 (1.9e4.6) <0.001 83 SR v SP [p Z 0.33] 4 (3e5) 1 (0e2)
SP 13.8 (6.3e17.5) 2.2 (1.2e5.1) <0.001 84 4 (3e5) 1 (0e2)
AAGSV 13.4 (8.3e16.3) 3.1 (1.8e4.2) <0.001 77 4 (2e5) 1 (0e2)
Perforator 12.1 (6.9e14.5) 3.6 (2.1e6.6) Z 0.004 70 4 (2e5) 1 (0e2)
a ManneWhitney u-test.
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the prevalence of this was not known in this series.
In the majority of patients with recurrent GSV reflux this
was secondary to groin neovascularisation although a few
had a relatively normal appearance to the SFJ on DUS when
it appeared that the tributaries had been previously ligated
but not the GSV. This is likely to reflect inadequate primary
surgery.
In patients with groin neovascularisation attempts were
made to obliterate the neo-vessels with STD foam adminis-
tered via the laser catheter. Although complete ablation of
all refluxing veins was rarely achieved (5/24) it is possible
that the extent of reflux was reduced in some patients with
persistent neo-vessels on follow-up DUS. Certainly no re-
recurrence or compromise in clinical outcome was docu-
mented due to persisting neovascularisation at 1 year. As the
degree of neovascularisation was not formally measured in
this study, it is not possible to comment further upon the
effectiveness of foam sclerotherapy in the treatment of
neovascularisation. Importantly however, there was no
evidence of DVT following the use of foam sclerotherapy to
treat neovascularisation. In respect of all other potential
complications these were similar in both patients with
primary varicose veins and those undergoing treatment for
recurrence.
In the UK SSV stripping is not routinely performed and
thus most RVVS due to SSV reflux were suitable for laser
ablation which is now the preferred method of treatment
for SSV related varicosities in our institution. In most
patients the SPJ had been ligated at the original surgery
and SSV reflux was the result of communication between
the axial vein and the popliteal vein via neovascularisation
which was often tortuous. Thus it was not possible toTable 5 Comparison of AVVSS and VCSS scores at 1 year. (All da
Groups n Z patients
(limbs)
Pre treatment
AVVSS
1 yr post-EVLA
AVVSS
Pa
GR n Z 42 (44) 14.2 (10.2e18.9) 2.1 (1.1e6.1) <0.
GP n Z 43 (43) 15.9 (11.4e22.7) 2.8 (1.2e5.9) <0.
SR n Z 20 (21) 14.4 (8.2e19.4) 2.2 (1.7e4.7) <0.
SP n Z 22 (22) 13.8 (6.3e17.5) 2.0 (1.1e4.9) <0.
AAGSV n Z 8 (10) 13.4 (8.3e16.3) 3.2 (1.7e4.9) <0.
Perforator n Z 4 (4) 12.1 (6.9e14.5) 3.2 (2.1e6.4) b
a Pre-EVLA versus Post EVLA (1 year) AVVSS, ManneWhitney u-test.
b Insufficient numbers to allow calculation of significance.achieve a flush SSV/SPJ ablation in most cases. Foam
sclerotherapy was not employed for neovascularisation at
this site as we had elected to evaluate its role in patients
with SFJ neovascularisation.
Although flush ablation of the axial/deep vein junction
was not possible in most patients with SSV/GSV reflux all
had a significant improvement in their symptoms scores
(AVVSS, VCSS). Whilst there may be some debate about the
optimum site for distal cannulation of the axial vein it is our
policy to commence ablation at the lowest point of reflux
when feasible. Although previous studies have reported
transient sural nerve damage in 1e4% of patients following
SSV EVLA,7,12 no instances of nerve injury occurred in
patients with recurrent GSV or SSV varicosities in this study
even when the SSV was ablated from the ankle. Careful
attention to the administration of tumescent anaesthesia is
likely to be the key to this. There was one transient sural
nerve injury in a patient with primary varicose veins
however.
Incompetent perforator veins may be associated with
distal axial vein reflux and RVVS. In this series successful
treatment was achieved by ablation of the axial veins
without specific intervention for the incompetent perfo-
rator. These regained competence following axial vein
ablation and this was associated with a symptomatic
improvement. Although endovenous ablation of incompe-
tent perforators has been reported by others13 this was not
performed in our unit during the study period. Thus
patients with incompetent perforating veins that con-
nected directly to the varicosities were offered surgical
treatment.
Ablation of an incompetent axial vein that connects
distal varicosities with a proximal source of reflux (groin orta are represented by the median and inter-quartile range).
% Improvement AVVSS Pre EVLA
VCSS
Post EVLA
VCSS (1 year)
001 85 GR v GP p Z 0.32 4 (3e5) 1 (0e2)
001 82 4 (3e5) 1 (0e2)
001 85 SR v SP p Z 0.39 4 (3e5) 1 (0e2)
001 86 4 (3e5) 1 (0e2)
001 76 4 (2e5) 1 (0e2)
74 4 (2e5) (0e2)
696 N.S. Theivacumar, M.J. Goughpopliteal fossa neovascularisation, incompetent perfo-
rating veins) appears to improve symptoms as measured by
AVVSS and to control the majority of visible varicosities
provided cannulation is performed distal to the lowest
point of reflux. For residual varicosities post-EVLA scle-
rotherapy was performed at the 6 week follow-up if
requested by the patient. Similar results were obtained
even when the recurrent varicosities arose from pelvic
veins, even though the feeding vein remained patent (but
with <1s reflux). Failure to recognise such communications
may result in unnecessary groin re-exploration since accu-
rate ligation is almost impossible to achieve by this means.
Clearly, varicosities arising from pelvic veins without an
interim axial vein are unlikely to be suitable for currently
available EVLA techniques.
Critics of this study might argue that the outcome of EVLA
for RVVS should have been compared with that of surgical
treatment. Given the different patterns of reflux that are
responsible for RVVS and our previous experience in
attempting to randomise patients between EVLA and
conventional surgery for primary varicose veins14 we felt
that it would be impossible to recruit sufficient numbers to
such a trial. Further surgical stripping of a residual GSV is not
always possible during re-exploration of the groin or popli-
teal fossa since the proximal vein may not be easily acces-
sible and if left in-situ further recurrence is likely (Fig. 1).
Although technical difficulty was not formally assessed,
unlike the difference between recurrent and primary
surgery, EVLA was no different to that when treating
primary varicose veins. Further, since it was often difficult
to pass the guide-wire from the axial vein into the deep
vein when treating RVVS the safety of the deep veins was
guaranteed.
Conclusions
In appropriate patients EVLA is a safe and effective treat-
ment for RVVS due to recurrent SFJ and SPJ reflux, perfo-
rator incompetence and pelvic vein reflux. Ablation of the
responsible axial vein improves symptoms as measured by
AVVSS and is associated with high levels of patient satis-
faction. This was apparent at both 3 month and 1 year
follow-up. Since the technique is relatively straightforward
and is not associated with more complications than EVLA
for primary varicose veins, the technique could be
preferred to conventional surgical treatment whenever the
anatomy is suitable. Long term follow is required, partic-
ularly to assess the significance of persisting neo-
vascularisation after EVLA.Conflict of Interest
None.
Funding
None.
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